Clinical Trial · NCT04411966

Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer

Overview

We aim to investigate the value of 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for early prediction of treatment response and survival in patients with metastatic breast cancer after salvage therapy.

Sponsor

Chang Gung Memorial Hospital

Phase

N/A

ClinicalTrials.gov

NCT04411966

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Participants must have histological evidence of breast cancer of any stage
Participants must be diagnosed with metastatic breast cancer
Participants should be willing and able to have both PET-CT scans
Participants must sign a study specific consent form prior to registration
Participants should be eligible for and plan to undergo systemic chemotherapy and should be seen by a oncologist prior to beginning the study

Exclusion

Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or significant inflammation at treatment site or psychiatric illness/social situations that would limit compliance with study requirements or whose lab values do not meet the criteria above are excluded
Breast feeding women are excluded from this study
Pregnant women are excluded from this study
Patients have been diagnosed with other malignancy